Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma

被引：0
|
作者：
Tongsen Zheng
Dalong Yin
Zhaoyang Lu
Jiabei Wang
Yuejin Li
Xi Chen
Yingjian Liang
Xuan Song
Shuyi Qi
Boshi Sun
Changming Xie
Xianzhi Meng
Shangha Pan
Jiaren Liu
Hongchi Jiang
Lianxin Liu
机构：
[1] the First Affiliated Hospital of Harbin Medical University,Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of General Surgery
[2] the First Affiliated Hospital of Harbin Medical University,Department of Gerontology
[3] Children’s Hospital Boston and Harvard Medical School,undefined
[4] Boston,undefined
来源：
Molecular Cancer | / 13卷
关键词：
Arsenic trioxide resistance; Nutlin-3; Metastasis; p53 mutation; p73; Hepatocellular carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
    Yee-Lin, Voon
    Pooi-Fong, Wong
    Soo-Beng, Alan Khoo
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2018, 18 (02) : 173 - 183
  • [22] Increasing Lung P53 By Nutlin-3 Prevents And Reverses Experimental Pulmonary Hypertension
    Mounaret, N.
    Gary-Bobo, G.
    Abid, S.
    Houssaini, A.
    Marcos, E.
    Noureddine, H.
    Saker, M.
    Amsellem, V.
    Dubois-Rande, J-L.
    Boczkowski, J.
    Boyer, L.
    Adnot, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [23] Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
    C F Cheok
    N Kua
    P Kaldis
    D P Lane
    Cell Death & Differentiation, 2010, 17 : 1486 - 1500
  • [24] p53 gene therapy for pulmonary metastasis tumor from hepatocellular carcinoma
    Yu, Miao
    Chen, Wei
    Zhang, Jinshan
    ANTI-CANCER DRUGS, 2010, 21 (09) : 882 - 884
  • [25] Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
    Cheok, C. F.
    Kua, N.
    Kaldis, P.
    Lane, D. P.
    CELL DEATH AND DIFFERENTIATION, 2010, 17 (09): : 1486 - 1500
  • [26] How Nutlin-3 disrupts the MDM2–p53 interaction: a theoretical investigation
    Shah Md. Abdur Rauf
    Hiromitsu Takaba
    Carlos A. Del Carpio
    Akira Miyamoto
    Medicinal Chemistry Research, 2014, 23 : 1998 - 2006
  • [27] PHARMACOLOGIC ACTIVATION OF THE P53 PATHWAY BY NUTLIN-3 INHIBITS MEDULLOBLASTOMA CELL PROLIFERATION IN VITRO
    Kuenkele, Annette
    de Preter, Katleen
    Vandesompele, Jo
    Pajtler, Kristian
    Heukamp, Lukas
    Grotzer, Michael
    Schramm, Alexander
    Eggert, Angelika
    Schulte, Johannes
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 918 - 918
  • [28] The MDM2 Inhibitor Nutlin-3 But Not the p53 Activator RITA Induces Loss-of-function p53 Mutations
    Michaelis, M.
    Rothweiler, F.
    Barth, S.
    Cinatl, J.
    van Rikxoort, M.
    von Deimling, A.
    Roedel, F.
    Speidel, D.
    Cinatl, J., Jr.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 43 - 43
  • [29] TUMOR PROGRESSION IN HEPATOCELLULAR-CARCINOMA MAY BE MEDIATED BY P53 MUTATION
    TANAKA, S
    TOH, Y
    ADACHI, E
    MATSUMATA, T
    MORI, R
    SUGIMACHI, K
    CANCER RESEARCH, 1993, 53 (12) : 2884 - 2887
  • [30] Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line
    Chan, KT
    Lung, ML
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (06) : 519 - 526
12345